Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05496036 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma
A Phase 2 study of Merkel Cell Carcinoma, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05496036: Recruiting Phase 2 study of Merkel Cell Carcinoma, sponsored by Abramson Cancer Center at Penn Medicine.
NCT05496036 is a Phase 2 study of Merkel Cell Carcinoma that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 15 participants, below the 50-participant average among 26 other Merkel Cell Carcinoma trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05496036, a Phase 2 study of Merkel Cell Carcinoma, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The main purpose of this study is to determine the response of Merkel cell carcinoma to pembrolizumab before surgery and to determine whether it further reduces the risk for disease recurrence. Another purpose of this study is to look at the side effects that occur when the experimental drug pembrolizumab is given to people with Merkel cell carcinoma before and after their standard of care surgery to remove the Merkel cell carcinoma.
Primary Outcome
The number of subjects with pathologic complete response (CR) or near CR defined by less than 10% viable tumor cells will be determined for subjects who received 1 dose of neoadjuvant pembrolizumab and underwent definitive surgery. PathCR/nearCR rate is defined as the percentage of treated subjects who achieve PathCR/nearCR
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (1)
Pennsylvania
- Penn Medicine - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2023-02-13 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 2 |
What NCT05496036 shows while recruiting
NCT05496036 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 50-participant average among 26 other Merkel Cell Carcinoma trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Merkel Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT05496036 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05496036 about?
NCT05496036 is a clinical study titled "Neoadjuvant PD-1 Blockade in Resectable Merkel Cell Carcinoma". The main purpose of this study is to determine the response of Merkel cell carcinoma to pembrolizumab before surgery and to determine whether it further reduces the risk for disease recurrence. Another purpose of this study is to look at the side effects that occur when the experimental drug pembrol...
What is the current status of trial NCT05496036?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2023-02-13. Estimated completion is 2027-09-30.
What conditions does trial NCT05496036 study?
This clinical trial studies the following conditions: Merkel Cell Carcinoma.
What interventions are being tested in trial NCT05496036?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT05496036?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05496036 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Merkel Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05496036's enrollment target sits among peer trials
15 22nd of 26 higher than 5 of 26 other Merkel Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Merkel Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIL Therapy in cSCC and MCC
RECRUITING · Phase 2
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
RECRUITING · Phase 2
-
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
RECRUITING · Phase 2
-
Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI